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ABSTRACT 
A series of 16 derivatives of pyrazole-triazole-chromene moieties (4a-p) were synthesized via one-pot cyclocondensation reaction of pyrazole-
triazole aldehyde (1a-d), 1, 3 diketone (3a-d) and malononitrile (2a) in presence of PS-TBD as catalyst. The reusability of PS-TBD (polystyrene 
supported 7-methyl-1, 5, 7-triazabicyclo [4.4.0] dec-5-ene) catalyst makes this reaction quick and efficient. On the basis of various trials and its 
results, best performance and reusability of catalyst was observed at 5 mol% concentration. The reusability of catalyst founds up to 5 runs. A 
synthesized compound was characterized by 1HNMR, 13CNMR, FT-IR and C, H, N elemental analysis and confirms theoretical chemical reaction. 
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1. INTRODUCTION 
Polymer-supported catalysts have an appeal much attention 
in recent decades due to their inherent advantages in green 
chemistry, for example, simplification of reaction procedures 
including the easy recovery of the catalyst by filtration, 
application to automated systems, and recycling of catalyst, 
In any polymer supported catalyst catalyzed a reaction, after 
the completion of reaction catalyst can be easy collected and 
reused catalyst.[1-4] Green chemistry emphasizes the 
development of environmentally benign chemical processes 
and technologies. So it will be equally beneficial for the 
environment as well as for the coast of green chemistry.[5] 
The Much Vantage of catalyst PS-TBD are reusability, 
cleanness and less harmful to the environment, makes the 
chemical reaction more eco-friendly, economic and 
environmental advantages.[6, ] The PS-TBD is a polymer-
supported organocatalyst consisting of a covalently linked 
guanidine TBD moiety to polystyrene which has been 
successfully used in a wide range of reactions, as epoxide 
ring opening, aldol-type condensation[7], Knoevenagel 
condensation[7], Michael additions[7] to α, β-unsaturated 
ketones, cyanosilylation of aldehydes, ketones, and imines[7], 
ring opening of aziridines and addition of dialkylphosphites 
to unsaturated systems. This series novel compounds 
softwood with polystyrene supported 7-methyl-1, 5, 7-
triazabicyclo [4.4.0] dec-5-ene (PS-TBD).pyrano[4, 3-b]pyran 
and pyrano[3, 2-c]chromene compounds. In the continuation 
of our previous work we use PS-TBD (polystyrene supported 
7-methyl-1, 5, 7-triazabicyclo[4.4.0]dec-5-ene) a catalyst for 
the one pot cyclocondesation reaction of triazole-pyrazole 
substituted aldehyde, various active methelene compounds, 
and malononitrile[8-12]. All synthesized compounds were 
characterized by various physicochemical methods. 
2. EXPERIMENTAL  
All the reagents and solvents were obtained commercially 
and used without further purification. All melting points 
were taken in open capillaries and are uncorrected. For 
monitoring the progress of all reactions and purity of the 
synthesized compounds thin-layer chromatography (TLC, 
on aluminium plates precoated with silica gel 60F254, Merck, 
Darmstadt, Germany) was used; eluent hexane: ethylacetate 
(1:1). UV radiation and/or iodine were used as the 
visualizing agents. The IR spectra were recorded Perkin-
Elmer Spectrum GX FT-IR Spectrophotometer (Perkin-
Elmer, USA), only the characteristic peaks are reported in 
cm-1. Elemental analysis (% C, H, N) was carried out by 
Perkin-Elmer 2400 series-II elemental analyzer (Perkin-
Elmer, USA); all compounds are within ±0.4% of theory 
specified. 1H NMR and 13C NMR spectra were recorded in 
DMSO-d6 on a BrukerAvance 400F (MHz) spectrometer 
(Bruker Scientific Corporation Ltd., Switzerland) using 
solvent peak as internal standard at 400 MHz and 100 MHz 
respectively. Chemical shifts are reported in parts per 
million (ppm). Mass spectra were scanned on a Shimadzu 
LCMS 2010 spectrometer (Shimadzu, Tokyo, Japan).  
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2.1. General procedure for the synthesis of targeted 
compounds 
2.1.1. Synthesis of 3-methyl-1-(4-substituted phenyl)-
5-(1H-1, 2, 4-triazol-1-yl)-1H-pyrazole-4-
carbaldehyde  
Triazole substituted aldehyde (1a-d) was synthesized by 
heating previously prepared 0.05 mole substituted 5-chloro-
3-methyl-1-(4-substituted phenyl)-1H-pyrazole-4-
carbaldehyde [13-15] (I) and 0.05 mole 1H-1, 2, 4-triazole (II) 
and 0.075 mole of anhydrous Potassium carbonate (K2CO3) in 
dimethyl formamide at 80°C for 2 hr. After the completion of 
reaction monitoring by TLC, the reaction mass was poured 
into crushed ice. The product obtained was filtered, washed, 
dried and recrystalized from ethyl acetate. 
 
[Scheme 1] 
 
2.1.2. General procedure for the synthesis of targeted 
compounds 4a-p 
Mixture of appropriate 3-methyl-1-(4-substituted phenyl)-5-
(1H-1, 2, 4-triazol-1-yl)-1H-pyrazole-4-carbaldehyde7 (1a–d) 
(5 mmol), malononitrile (2a) (5 mmol), 1, 3- 
cyclohexanedione (3a) / dimedone8 (3b) / 4-hydroxy-6-
methyl-2H-pyran-2-one (3c) / 4-hydroxy-coumarin (3d) (5 
mmol) and PS-TBD (5 mol %) in ethanol (5 ml) were charged 
in 100 ml round bottom flask equipped with condenser. The 
reaction mixture was stirred at reflux for 1.5 h. After 
completion of the reaction, as evidenced by TLC, the solid 
precipitated was dissolved by adding 15 ml chloroform: 
methanol (1:1). PS-PBD, which remained insoluble was 
collected by filtration and separately washed with 10 ml 
acetone and dried in oven to activate for the next batch. The 
filtrate was concentrated under vacuum to get solid and 
filtered (yield 86%–95%). The crude product was 
recrystallized from 50 ml chloroform: methanol (9:1) to get a 
pure solid sample. PS-TBD maintained its catalytic activity up 
to five runs.[16, 17] 
 
 
[Scheme 2] 
Table 1: Optimization of reaction condition for 4a 
Entry Temperature 
  C  
Time 
(h) 
Mol % 
PS-TBD 
%Yield a 
1 RT 2 - 56 
2 60 2 2 72 
3 80 2 2 75 
4 80 1.5 5 88 
5 80 1.5 8 ~88 
a Isolated yield 
3- Phenyl-5-(1H-1, 2, 4-triazol-1-yl)-1H-pyrazole-4-carbaldehyde1a (5 mmol), malononitrile 2(5 mmol) and 4-hydroxy 
coumarin 6(5 mmol) 
Table 2: Activity of reused catalyst for synthesis of 4a 
Run %Yielda 
1st 88 
2nd 85 
3rd 81 
4th 76 
5th 73 
a a Isolated yield 
2-amino-4-(3-methyl-1-phenyl-5-(1H-1, 2, 4-triazol-1-yl)-1H-pyrazol-4-yl)-5-oxo-5, 6, 7, 8-tetrahydro-4H-chromene-3-
carbonitrile (4a) 
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White solid(1.689g, 96%), mp223°C;IR(KBr):ν=3428, 3344, 
2189, 1677, 1241cm-1; 1H NMR (400 MHz, DMSO-d6) δ = 1.93 
(3H)1.94 -2.92 (6H, m, 3×CH2), 4.23 (1H, s, H4), 7.58-8.54(8H, 
m, Ar-H+NH2), 6.84(2H, s, NH) ppm; MS calcd. for C22H19N7O2 
[M]+ 413.16, found 413.44;Anal. calcd. C, 63.91; H, 4.63; N, 
23.72; O, 7.74; Found: C, 64.19; H, 4.43; N, 23.40; O, 7.59 % 
13C NMR , 13.1, 21.3, 28.2, 29.0, 36.6, 58.3, 112.4, 118.9, 119.3, 
199.4, 119.5, 125.7, 129.5, 129.9, 139.7, 147.5, 151.3, 152.4, 
154.3, 155.4 , 159.5, 198.2. 
2-amino-4-(1-(4-chlorophenyl)-3-methyl-5-(1H-1, 2, 4-
triazol-1-yl)-1H-pyrazol-4-yl)-5-oxo-5, 6, 7, 8-tetrahydro-4H-
chromene-3-carbonitrile (4b) 
White solid (1.729 g, 96%), mp 225 °C; IR (KBr):ν =3416, 
3356, 2195, 1673, 1241 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
= 1.92(3H), 1.93-2.93(6H m, 3×CH2), 4.23 (1H, s, H4), 7.58-
8.26(8H, m, Ar-H+NH2), 6.84(2H, s, NH) ppm; MS calcd. for 
C22H18ClN7O2 [M]+447.12, found447.88;Anal. calcd. C, C, 
59.00; H, 4.05; Cl, 7.92; N, 21.89; O, 7.14; Found: C, 59.31; H, 
4.17; Cl 7.52; N, 21.95; O, 6.93%; 13C NMR 12.9, 21.5, 28.5, 
28.9, 36.9, 58.4, 113.0 , 118.0, 118.2, 118.5, 118.8, 129.6, 
130.3, 131.6, 137.9, 147.5, 151.5, 152.7, 154.6, 155.0, 158.2, 
197.5. 
2-amino-4-(3-methyl-1-(p-tolyl)-5-(1H-1, 2, 4-triazol-1-yl)-
1H-pyrazol-4-yl)-5-oxo-5, 6, 7, 8-tetrahydro-4H-chromene-3-
carbonitrile (4c) 
White solid (1.619 g, 95%), mp 224 °C; IR (KBr):ν = 3399, 
3365, 2195, 1673, 1255 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
= 1.94 (3H), 1.94-2.92 (6H, m, 3×CH2), 4.32 (1H, s, H4), 7.25-
7.51(8H, m, Ar-H+NH2), 6.80(1H, s, NH) ppm; MS calcd. for 
C23H21N7O2 [M]+ 427.18, found 427.47;Anal. calcd. C, 64.63; H, 
4.95; N, 22.94; O, 7.49; Found: C, 64.39; H, 5.13; N, 22.61; O, 
7.12% 13C NMR, 13.0, 21.6, 21.6, 28.6, 28.6, 36.7, 57.5, 113.2, 
119.2, 119.6, 125.2, 125.5, 129.0, 129.1, 135.8, 136.9, 146.2, 
151.3, 152.4, 154.1, 155.3, 159.4, 197.8. 
2-amino-4-(1-(4-methoxyphenyl)-3-methyl-5-(1H-1, 2, 4-
triazol-1-yl)-1H-pyrazol-4-yl)-5-oxo-5, 6, 7, 8-tetrahydro-4H-
chromene-3-carbonitrile (4d) 
White solid (1.889 g, 96%), mp 224 °C; IR (KBr):ν = 3374, 
3295, 2208, 1677, 1275 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
= (3H), 1.92-2.89(6H m, 3×CH2), 4.11 (1H, s, H4), 6.980-7.632 
(8H, m, Ar-H+NH2), 6.66(1H, s, NH) ppm; MS calcd. for 
C23H21N7O3 [M]+ 443.17, found 443.47;Anal. calcd. C, 62.29; H, 
4.77; N, 22.11; O, 10.82 Found: C, 62.41; H, 4.52; N, 21.86; O, 
10.99 % 13C NMR, 13.3, 20.7, 28.4, 28.5, 35.9, 55.5, 57.1, 
111.9, 112.5, 113.0, 114.5, 114.9, 119.1, 119.4, 132.2, 147.4, 
151.3, 152.5, 154.8, 155.4, 158.3, 159.5, 198.2. 
2-amino-7, 7-dimethyl-4-(3-methyl-1-phenyl-5-(1H-1, 2, 4-
triazol-1-yl)-1H-pyrazol-4-yl)-5-oxo-5, 6, 7, 8-tetrahydro-4H-
chromene-3-carbonitrile (4e) 
White solid (1.589 g, 96%), mp 222 °C; IR (KBr):ν = 3352, 
3365, 2195, 1675, 1202 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
= 1.91 (3H), 1.01-2.32 (6Hm, 3×CH2), 4.21 (1H, s, H4), 7.49-
8.26(8H, m, Ar-H+NH2), 6.85(1H, s, NH) ppm; MS calcd. for 
C24H23N7O2 [M]+ 441.19, found441.50;Anal. calcd. C, 65.29; H, 
5.25; N, 22.21; O, 7.25; Found: C C, 65.44; H, 5.58; N, 22.37; O, 
7.05 % 13C NMR, 13.2, 20.5, 27.1, 28.0, 32.2, 38.3, 50.9, 57.8, 
113.7, 118.6, 118.8, 119.3, 119.9, 126.5, 129.1, 129.6, 139.9 
147.8, 151.7, 152.4, 154.9, 155.6, 159.4, 197.9. 
2-amino-4-(1-(4-chlorophenyl)-3-methyl-5-(1H-1, 2, 4-
triazol-1-yl)-1H-pyrazol-4-yl)-7, 7-dimethyl-5-oxo-5, 6, 7, 8-
tetrahydro-4H-chromene-3-carbonitrile (4f) 
White solid (1.569 g, 94%), mp218°C;IR(KBr):ν=3419, 3362, 
2195, 1667, 1213cm-1;1H NMR(400 MHz, DMSO-d6)δ 
=1.93(3H), 1.12-2.30 (6H, m, 3×CH2), 4.26 (1H, s, H4), 7.31-
7.56(8H, m, Ar-H+NH2), 6.78(1H, s, NH) ppm; MS calcd. for 
C24H22ClN7O2 [M]+ 475.15, found475.94;Anal. calcd. C, 60.57; 
H, 4.66; Cl, 7.45; N, 20.60; O, 6.72; Found: C, 60.23; H, 4.73; Cl, 
7.67; N, 20.21; O, 6.45%  13CNMR, 13.0, 27.4,  27.4, 28.2, 32.6, 
38.7, 51.1, 58.0, 114.2, 119.0, 119.4, 119.7, 120.0, 129.1, 
129.7, 131.9, 138.0, 146.8, 151.3, 152.5, 154.5, 155.3, 159.8, 
198.4. 
2-amino-7, 7-dimethyl-4-(3-methyl-1-(p-tolyl)-5-(1H-1, 2, 4-
triazol-1-yl)-1H-pyrazol-4-yl)-5-oxo-5, 6, 7, 8-tetrahydro-4H-
chromene-3-carbonitrile (4g) 
White solid (1.489 g, 92%), mp 219 °C; IR (KBr):ν 3444, 3317, 
2196, 1642, 1254 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
=1.93(3H), 1.81-2.78 (6H, m, 3×CH2), 4.31 (1H, s, H4), 7.27-
7.57(8H, m, Ar-H+NH2), 6.91(1H, s, NH) ppm; MS calcd. for 
C25H25N7O2 [M]+ 455.21, found455.52;Anal. calcd. C, 65.92; H, 
5.53; N, 21.52; O, 7.02; Found: C, 66.17; H, 5.76; N, 21.79; O, 
7.56% 13C NMR, 13.5, 21.5, 27.9, 26.7, 28.2, 32.5, 38.8, 51.7, 
58.3, 113.5, 119.3, 119.6, 124.9, 125.3, 129.5, 129.9, 135.5, 
136.5, 147.6, 151.9, 152.3, 154.6, 155.5, 159.7, 198.7. 
2-amino-4-(1-(4-methoxyphenyl)-3-methyl-5-(1H-1, 2, 4-
triazol-1-yl)-1H-pyrazol-4-yl)-7, 7-dimethyl-5-oxo-5, 6, 7, 8-
tetrahydro-4H-chromene-3-carbonitrile (4h) 
White solid (1.509 g, 95%), mp 220 °C; IR (KBr):ν 3449, 3373, 
2203, 1672, 1214 cm-1; 1H NMR (400 MHz, DMSO-d6) δ = 
1.94(3H), 1.81-2.50 (6H, m, 3×CH2), 4.23 (1H, s, H4), 7.31-
7.66(8H, m, Ar-H+NH2), 6.91(1H, s, NH) ppm; MS calcd. for 
C25H25N7O3 [M]+471.20found471.52;Anal. calcd. C, 63.68; H, 
5.34; N, 20.79; O, 10.18; Found: C, 63.99; H, 5.03; N, 20.47; 0, 
10.58% 13C NMR, 13.4, 27.1, 27.3, 28.2, 32.3, 38.7, 51.2, 54.9, 
58.7, 112.6, 112.9, 113.5, 114.7, 115.0, 118.9, 119.3, 132.2, 
147.5, 151.2, 152.6, 154.4, 155.2 , 158.5, 159.6, 199.2. 
2-amino-7-methyl-4-(3-methyl-1-phenyl-5-(1H-1, 2, 4-
triazol-1-yl)-1H-pyrazol-4-yl)-5-oxo-4H, 5H-pyrano [4, 3-b] 
pyran-3-carbonitrile (4i) 
White solid (1.250 g, 91%), mp 221 °C; IR (KBr):ν = 3416, 
3364, 2195, 1673, 1241 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
=1.91(3H), 2.21-6.42 (6H, m, 4×CH2), 4.41 (1H, s, H4), 7.25-
8.56(8H, m, Ar-H+NH2), 6.82(1H, s, NH) ppm; MS calcd. for 
C22H17N7O3 [M]+ 427.14, found427.42;Anal. calcd. C, 61.82; H, 
4.01; N, 22.94; O, 11.23; Found: C, 61.91; H, 3.88; N, 23.08; O, 
11.51% 13C NMR, 12.9, 21.1, 29.8, 58.1, 100.3, 100.5, 118.3, 
118.9, 119.2, 119.4, 126.4, 129.2, 129.8, 139.1, 147.1, 151.1, 
152.2, 154.5, 158.9, 162.1, 163.2, 175.5. 
2-amino-4-(1-(4-chlorophenyl)-3-methyl-5-(1H-1, 2, 4-
triazol-1-yl)-1H-pyrazol-4-yl)-7-methyl-5-oxo-4H, 5H-
pyrano [4, 3-b] pyran-3-carbonitrile (4j) 
White solid (1.189 g, 89%), mp 219 °C; IR (KBr):ν = 3419, 
3335, 2194, 1673, 1249 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
=1.91(3H), 2.32-6.23 (6H, m, 4×CH2), 4.43 (1H, s, H4), 7.34-
7.56(8H, m, Ar-H+NH2), 6.67(1H, s, NH) ppm; MS calcd. for 
C22H16ClN7O3 [M]+ 461.10, found461.87;Anal. calcd. C, 57.21; 
H, 3.49; Cl, 7.68; N, 21.23; O, 10.39; Found: C, 56.78; H, 3.88; 
Cl, 7.23; N, 21.76; O, 10.01%13CNMR, 12.7, 21.0, 30.1, 58.3, 
100.6, 100.7, 119.1, 119.8, 119.9, 120.8, 129.1, 129.6, 131.4, 
136.6, 146.1, 151.3, 152.2, 154.6, 158.2, 161.6, 163.2, 175.1. 
2-amino-7-methyl-4-(3-methyl-1-(p-tolyl)-5-(1H-1, 2, 4-
triazol-1-yl)-1H-pyrazol-4-yl)-5-oxo-4H, 5H-pyrano [4, 3-b] 
pyran-3-carbonitrile (4k) 
White solid (1.289 g, 90%), mp 223 °C; IR (KBr):ν = 3414, 
3378, 2192, 1671, 1252 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
= 1.94(3H)2.43-6.43 (6H, m, 4×CH2), 4.21 (1H, s, H4), 7.27-
7.58(8H, m, Ar-H+NH2), 6.43(1H, s, NH) ppm; MS calcd. for 
C23H19N7O3 [M]+ 441.15, found441.45;Anal. calcd. C, 62.58; H, 
4.34; N, 22.21; O, 10.87; Found: C, 62.69; H, 3.67; N, 22.50; O, 
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11.21% 13C NMR, 12.9, 19.8, 21.4, 30.5, 58.7, 100.3, 100.8, 
119.0, 119.8, 125.1, 125.8, 129.6, 129.9, 134.7, 136.2, 147.4, 
151.2, 152.8, 154.2, 160.1, 162.2, 163.6, 174.5. 
2-amino-4-(1-(4-methoxyphenyl)-3-methyl-5-(1H-1, 2, 4-
triazol-1-yl)-1H-pyrazol-4-yl)-7-methyl-5-oxo-4H, 5H-
pyrano [4, 3-b] pyran-3-carbonitrile (4l) 
White solid (1.342 g, 90%), mp 224 °C; IR (KBr):ν = 3375, 
3385, 2192, 1665, 1252 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
= 1.93(3H)2.46-6.64 (8H, m, 4×CH2), 4.36 (1H, s, H4), 7.27-
7.62(8H, m, Ar-H+NH2), 6.55(1H, s, NH) ppm; MS calcd. for 
C23H19N7O4 [M]+457.15, found457.45;Anal. calcd C, 60.39; H, 
4.19; N, 21.43; O, 13.99; Found: C, 60.02; H, 4.53; N, 21.88; O, 
13.25% 13C NMR, 12.8, 20.7, 28.5, 55.1, 58.2, 100.4, 101.2, 
112.0, 112.2, 113.9, 114.5, 119.0, 119.4, 132.2, 147.4, 151.2, 
152.5, 154.7, 158.1, 158.8, 160.2, 162.4, 172.3. 
2-amino-4-(3-methyl-1-phenyl-5-(1H-1, 2, 4-triazol-1-yl)-
1H-pyrazol-4-yl)-5-oxo-4H, 5H-pyrano [3, 2-c] chromene-3-
carbonitrile (4m) 
White solid (1.328 g, 92%), mp 225 °C; IR (KBr):ν = 3416, 
3356, 2195, 1673, 1241 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
=1.92(3H), 7.39-7.82 (8H, m, 4×CH2), 4.41 (1H, s, H4), 7.50-
8.43(8H, m, Ar-H+NH2), 6.91(1H, s, NH) ppm; MS calcd. for 
C25H17N7O3 [M]+463.14, found463.46;Anal. calcd. C, 64.79; H, 
3.70; N, 21.16; O, 10.36; Found: C, 64.21; H, 3.69; N, 21.35; O, 
10.56% 13C NMR, 12.9, 29.4, 57.7, 104.6, 115.3, 116.8, 118.8, 
119.1, 119.5, 119.9, 123.3, 125.5, 126.6, 128.1, 129.2, 129.6, 
139.1, 147.6, 151.2, 152.3, 153.2, 154.7, 159.2, 160.4, 162.3. 
2-amino-4-(1-(4-chlorophenyl)-3-methyl-5-(1H-1, 2, 4-
triazol-1-yl)-1H-pyrazol-4-yl)-5-oxo-4H, 5H-pyrano [3, 2-c] 
chromene-3-carbonitrile (4n) 
White solid (1.502 g, 93%), mp 220 °C; IR (KBr):ν = 3426, 
3366, 2195, 1673, 1249 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
=1.94(3H), 7.38-7.82 (8H, m, 4×CH2), 4.43 (1H, s, H4), 7.53-
7.52(8H, m, Ar-H+NH2), 6.92(1H, s, NH) ppm; MS calcd. for 
C25H16ClN7O3 [M]+497.10, found 497.90; Anal. calcd. C, 60.31; 
H, 3.24; Cl, 7.12; N, 19.69; O, 9.64; Found: C, 60.63; H, 3.09; Cl, 
6.69; N, 19.04; O, 9.14% 13CNMR, 13.1, 29.2, 58.0, 104.2, 
115.8, 116.5, 118.3, 119.1, 119.5, 119.8, 122.7, 125.4, 127.2, 
129.1, 29.4, 131.4, 137.3, 147.2, 150.7, 152.5, 152.8, 154.2, 
158.2, 160.1, 162.3. 
2-amino-4-(3-methyl-1-(p-tolyl)-5-(1H-1,2, 4-triazol-1-yl)-
1H-pyrazol-4-yl)-5-oxo-4H, 5H-pyrano [3, 2-c] chromene-3-
carbonitrile (4o) 
White solid (1.677 g, 95%), mp 219 °C; IR (KBr):ν = 3391, 
3313, 2193, 1665, 1256 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
= 1.93(3H)7.41-7.86 (8H, m, 4×CH2), 4.29 (1H, s, H4), 7.14-
7.56(8H, m, Ar-H+NH2), 6.95(1H, s, NH) ppm; MS calcd. for 
C26H19N7O3 [M]+ 477.15, found477.48;Anal. calcd. C, 65.40; H, 
4.01; N, 20.53; O, 10.05; Found: C, 66.77; H, 4.45; N, 20.56; O, 
10. 54% 13C NMR 13.1, 21.7, 29.1, 57.9, 105.5, 115.0, 116.2, 
119.0, 119.5, 123.3, 125.1, 125.3, 126.1, 128.3, 129.2, 129.8, 
135.2, 136.1, 147.0, 151.2, 152.1, 152.5, 154.2, 159.5, 160.3, 
161.4. 
2-amino-4-(1-(4-methoxyphenyl)-3-methyl-5-(1H-1, 2, 4-
triazol-1-yl)-1H-pyrazol-4-yl)-5-oxo-4H, 5H-pyrano [3, 2-c] 
chromene-3-carbonitrile (4p) 
White solid (1.803 g, 97%), mp 223 °C; IR (KBr):ν =3392, 
3318, 2193, 1664, 1253 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
= 1.90(3H)7.42-7.77 (8H, m, 4×CH2), 4.42 (1H, s, H4), 6.85-
7.60(8H, m, Ar-H+NH2), 6.98(1H, s, NH) ppm; MS calcd. for 
C26H19N7O4 [M]+ 493.15, found493.48;Anal. calcd C, 63.28; H, 
3.88; N, 19.87; O, 12.97; Found: C, 62.65; H, 4.11; N , 20.22; O, 
12.54% 13C NMR, 13.4, 29.4, 55.5, 58.5, 105.2, 112.1, 112.2, 
114.9, 115.0, 115.2, 116.6, 119.5, 119.7, 123.1, 125.1, 127.9, 
132.3, 147.4, 151.2, 152.1, 152.5, 154.1, 158.4, 159.1, 160.6, 
161.5. 
3. RESULTS AND DISCUSSION  
3.1. Chemistry  
A series of 16 compounds, 4H-chromene 4a–d and 4e–h, 
pyrano[4, 3-b]pyran 4i–l and pyrano[3, 2-c]chromene 4m–p 
were synthesized by the plausible reaction mechanism 
depicted in Scheme 2. The reaction was optimized by varying 
temperature, time and amount of catalyst (Table 1). We 
found that reaction of 3-methyl-1-(4-substituted phenyl)-5-
(1H-1, 2, 4-triazol-1-yl)-1H-pyrazole-4-carbaldehyde 1a-d, 
malononitrile (2a) and 4- hydroxy-coumarin (3d) with 5 
mol% PS-TBD, in ethanol at 80°C for 1.5 h gave 95% yield of 
4a. Further increasing loading of catalyst didn’t impact on 
yield. The catalytic activity of PS-TBD was investigated and it 
was found that PS-TBD maintained its efficiency up to five 
runs (Table 2). The newly synthesized compounds were 
characterized by 1H NMR, 13C NMR, FT-IR and elemental 
analysis. The molecular weight of compounds was confirmed 
by mass spectrometry. Physical, analytical and spectroscopic 
characterization data of all compounds are given in 
Supplementary material. 1H NMR (DMSO-d6) spectrum of 4a 
exhibited a singlet peak around 4.23 ppm stands for H4 
proton. Amine and aromatic protons of 4a resonate as 
multiplets at around 7.58–8.54 ppm. 13C NMR (DMSO- d6) 
spectrum shows characteristic peak at 28.6 ppm for cyclized 
carbon, 58.3 ppm for C–CN, 119.3 ppm for C≡N, 152.4 ppm 
for C– NH2 and 159.5 ppm for C=O, all these peaks support 
the structure of 4a. The IR spectrum of compound 4a 
exhibited characteristic absorption bands around 3428–
3344 cm-1 and 2189 cm-1 stands for (asym. & sym. 
stretching) –NH2 and –CN functional groups, respectively. 
The characteristic absorption band of C=O stretching and C–
O–C ether stretching are observed around 1677 cm-1 and 
1241 cm-1.  
The plausible reaction mechanism can be discussed as, in the 
first step, heterylidenenitrile forms by the Knoevenagel 
condensation of 3-methyl-1-(4-substituted phenyl)-5-(1H-1, 
2, 4-triazol-1-yl)-1H-pyrazole-4-carbaldehyde (4a–d) and 
pre-activated malononitrile 2a in the presence of PS-TBD. 
The catalyst PS-TBD abstracts the acidic proton of 
malononitrile and makes it more nuclophilic towards a facial 
attack on the carbonyl carbon of aldehyde. In second step, 
Michael addition of activated (3a-d) on heterylidenenitrile 
results into targeted molecules (4a–p). The catalyst is used 
in another cycle for synthesis of targeted molecules. 
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[Scheme 3] 
4. CONCLUSION 
In summary, use of PS-TBD as a reusable catalyst is proved 
to be very effective for the synthesis of titled compounds. 5 
mol% PS-TBD showed good catalytic activity up to five runs 
with good yield of desired products in less time, that reduce 
economical cost and environmental pollution.  
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